Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
4/17/2013 9:11:21 AM
More...
|
Omthera Pharmaceuticals, Inc. Prices Upsized IPO Below the Range at $8
4/11/2013 8:23:12 AM
More...
|
Omthera Pharmaceuticals, Inc. Files for a $75 Million IPO
3/11/2013 8:59:43 AM
More...
|
Omthera Pharmaceuticals, Inc. Presents Data From Analysis of EVOLVE Trial Showing That Epanova Lowers ApoC-III, a Key Predictor of Cardiovascular Risk
11/9/2012 11:39:04 AM
More...
|
Omthera Pharmaceuticals, Inc. Blasts Competitor Out of the Way as Omega-3 Makes Headlights in Phase 3 Study
11/5/2012 11:08:32 AM
More...
|
Omthera Pharmaceuticals, Inc. Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
11/2/2012 10:12:23 AM
More...
|
Omthera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4/26/2012 7:47:18 AM
More...
|
Omthera Pharmaceuticals, Inc. to Present at Leerink Swann and Company 2012 Global Healthcare Conference and Citi 2012 Global Healthcare Conference
2/15/2012 10:26:22 AM
More...
|
Omthera Pharmaceuticals, Inc. Announces Positive Long Term Bioavailability Data Comparing Epanova(TM) to Lovaza(R)
1/9/2012 12:10:22 PM
More...
|
Omthera Pharmaceuticals, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
1/5/2012 10:08:55 AM
More...
|
|